Implementing Ultra-high-pressure LC (UHPLC) in Pharmaceutical Analysis: Best Practices and Potential Issues
This Wednesday morning symposium was arranged by Michael Dong of Genentech (San Francisco, California), who also participated in LCGC?s Pittcon Theater on Monday.
Session 1320
Room 316, 8:00 a.m.
This Wednesday morning symposium was arranged by Michael Dong of Genentech (San Francisco, California), who also participated in LCGC’s Pittcon Theater on Monday.
Dong will kick off this symposium with his opening remarks followed by a presentation entitled, "UHPLC in Pharmaceutical Analysis: Perspectives, Performance and Issues." This will be a great session to attend for anyone who came to Monday's Pittcon Theater presentation by Dong- and for those who didn't as well!
After this presentation, Naijun Wu from Merck and Co. will take the stage with a discussion on UHPLC in pharmaceutical process development. Next up will be Klaus Witt from Agilent Technologies who will be discussing issues and solutions with method transfer between HPLC and UHPLC.
Qinglin Tang from Merck and Co. will present, "Implementation of UHPLC in Pharmaceutical QC Laboratories," next. The final presentation in this group will come from Taylor Zhang of Genentech and will discuss UHPLC for therapeutic protein characterization.
The Complexity of Oligonucleotide Separations
January 9th 2025Peter Pellegrinelli, Applications Specialist at Advanced Materials Technology (AMT) explains the complexity of oligonucleotide separations due to the unique chemical properties of these molecules. Issues such as varying length, sequence complexity, and hydrophilic-hydrophobic characteristics make efficient separations difficult. Separation scientists are addressing these challenges by modifying mobile phase compositions, using varying ion-pairing reagents, and exploring alternative separation modes like HILIC and ion-exchange chromatography. Due to these complexities, AMT has introduced the HALO® OLIGO column, which offers high-resolution, fast separations through its innovative Fused-Core® technology and high pH stability. Alongside explaining the new column, Peter looks to the future of these separations and what is next to come.
Metabolomics Analysis of Low Birth-Weight Infants Using UHPLC-MS/MS Following Lipid Emulsion
January 10th 2025A recent study aimed to directly compare the changes in serum metabolites among very low birth-rate (VLBW) infants following the administration of the soybean oil-based lipid emulsion and soybean oil, medium-chain triglycerides, olive oil, and fish oil (SMOF) lipid emulsion using untargeted metabolomics techniques.
Analyzing New Drug Modalities: An ISC 2024 Interview with Kelly Zhang
January 10th 2025At ISC 2024 in Liverpool, United Kingdom, LCGC International interviewed Kelly Zhang of Genentech about her work analyzing new drug modalities, such as mRNA, oligonucleotides, peptides, and cell and gene therapies.
